Treatment with fully human monoclonal antibodies against programmed death 1 (anti-PD1) have demonstrated great promise for the treatment of a number of advanced malignancies.
Abstract:
Treatment with fully human monoclonal antibodies against programmed death 1 (anti-PD1) have demonstrated great promise for the treatment of a number of advanced malignancies.
While inflammatory adverse events have been well-described with anti-Cytotoxic T-Lymphocyte Antigen (CTLA4) therapy, experience with the range of adverse effects of anti-PD1 remains comparatively limited.
Here, we report a patient with advanced mucosal melanoma who received four doses of MK-3475, a fully human monoclonal antibody against PD1, and experienced a durable near complete response, but developed severe hypothyroidism, rhabdomyolysis and acute kidney injury. To our knowledge, this is the first case reported of a patient with advanced mucosal melanoma who responded to anti-PD1 therapy. With the promising antitumor effects of anti-PD1 in a wide array of tumors, we expect an increasing number of patients to be exposed to anti-PD1 therapies. Recognition of infrequent presentations of adverse events such as elevated CK levels and thyroid disorders in patients who receive anti-PD1 therapy is important.
received one course of 30 Gray in 10 fractions radiotherapy to cervical vertebrae 6-thoracic 27 vertebrae 1 (C6-T1), which involved radiation exposure to parts of the thyroid gland. During MK-28 3475 therapy, he had thyroid function tests (TFTs) routinely as per the clinical trial protocol. 29
During the first fifteen weeks of anti-PD1 therapy (5 doses), he had normal TFTs and remained 30 active. Upon presentation to the clinic for evaluation prior to his sixth dose of MK-3475, he 31 complained of significant myalgias, tender muscles, and fatigue. He was hospitalized following 32 laboratory results that were significant for elevated transaminases: aspartate transaminase 33 PD1 is an immune-checkpoint receptor that negatively regulates T cell activation (8) . Anti-PD1 52 antibody induces durable responses in patients with advanced solid tumors (3, 6) . The current 53 patient with mucosal melanoma, a rare form of melanoma, had an initial near complete 54 response to MK-3475 therapy ( Figure 2 ) and has remained in remission for 14 months after 55 discontinuing treatment. Our understanding of immunotherapy efficacy in patients with mucosal 56 melanoma is inadequate. A recent study showed that in patients with mucosal melanoma the 57 overall response rate to ipilimumab therapy is low (9) . Here, we report the first case of a patient 58 with metastatic mucosal melanoma who experienced a durable response to anti-PD1 treatment 59 following CTLA4 blockade. Our findings provide insight for immunotherapy efficacy in patients 60 with mucosal melanoma as well as inform future drug development. Severe hypothyroidism is 61 likely associated with the MK-3475 therapy or a combined effect of ipilimumab followed by MK-62 3475. It is unlikely that this is a sole effect of ipilimumab since time to onset of ipilimumab-63 related endocrinopathies including thyroiditis is usually between 7 to 20 weeks of initial 64 ipilimumab therapy (10, 11) . This patient remained euthyroid for 43 weeks after completing 65 ipilimumab. Radiation-induced hypothyroidism is usually subclinical (12) but whether radiation 66 precipitates immunotherapy-related autoimmunity is unknown. His rhabdomyolysis could be a 67 consequence of hypothyroidism or autoimmune-related myositis. The patient did not receive any 68 glucocorticoid treatment. Since normalization of TFTs by levothyroxine replacement was 69 associated with normalization of his CK, it is likely that his rhabdomyolysis is directly associated 70 with the severe and acute onset of hypothyroidism. Nonetheless, given the nature of 71 inflammatory adverse events associated with anti-PD1 therapy, autoimmune myositis and 72
hepatitis cannot be excluded. The association of hypothyroidism with rhabdomyolysis and acute 73 renal injury has been reported (13); this female patient was presented with weakness, anorexia, 74 dysuria, and typical signs of severe hypothyroidism including hypothermia, hoarse voice andmetal status change. She also had a long history of Hashimoto thyroiditis but stopped thyroid 76 hormone replacement several years prior to her presentation. The relatively mild signs of 77 hypothyroidism in our case correlate well with its nature of rapid onset. Both patients had 78 remarkably high TSH and very low T4, elevated CK, creatinine, and aminotransferase. 79
Replacement with levothyroxine corrected the biochemical abnormalities in both cases. Prior to 80 beginning levothyroxine replacement, it is important to rule out adrenal insufficiency that is a 81 relatively common adverse event in patients receiving immunotherapy, as levothyroxine may 82 trigger adrenal crisis in patients with uncorrected adrenal insufficiency (14) . The initial dose of 83 levothyroxine depends on the age and heart condition of the patient. In young patients without 84 heart disease such as in this case, the average replacement dose of T4 is approximately 1.6 85 mcg/kg body weight daily, but the range of required doses is broad. For further levothyroxine 86 dose titration, TSH and free T4 should be measured 4-6 weeks after the initiation of 87 levothyroxine replacement. In older patients or patients with coronary artery disease, 88 levothyroxine should be started at a low dose, usually 12. 
